TickerFacts.

ADMA Biologics, Inc. (ADMA): Share Repurchases

Annual figures by period end, from SEC filings.

$31.94M
Year ended 2025-12-31
$187.19M
Trailing 12 months to 2026-06-30
2011-12-31: $02012-12-31: $150.0K2023-12-31: $02024-12-31: $02025-12-31: $31.94M$31.94M
2011-12-31 Share Repurchases (USD) 2025-12-31
Period endedShare RepurchasesChange YoYSource filing
2025-12-31$31.94Mn/a2026-02-25, From 2025-01-01
2024-12-31$0n/a2026-02-25, From 2024-01-01
2023-12-31$0n/a2026-02-25, From 2023-01-01
No annual figure between 2012-12-31 and 2023-12-31.
2012-12-31$150.0Kn/a2014-03-28, From 2012-01-01
2011-12-31$0n/a2013-03-06, From 2011-01-01

Share Repurchases at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShare RepurchasesChange YoY
ADMA Biologics, Inc. (ADMA)2025-12-31$31.94Mn/a
Repligen Corp (RGEN)2025-12-31$0n/a
Bio-Techne Corp (TECH)2026-06-30$41.67M-84.9%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$342.37M+36.9%
Moderna, Inc. (MRNA)2025-12-31$2.00Mn/a
Qiagen N.V. (QGEN)2025-12-31$280.09M-4.1%
Exelixis, Inc. (EXEL)2026-01-02$947.51M+45.3%
Neurocrine Biosciences Inc (NBIX)2025-12-31$167.70M-44.1%
Champions Oncology, Inc. (CSBR)2025-04-30$0-100.0%

Compare ADMA, RGEN, TECH, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗